Filter byLast updatedSelectAfterBeforeFrom - ToDateEnd DateCategoryHumanCorporateTopicCOVID-19MedicinesAdvanced therapiesAntimicrobial resistanceBiologicalsBiosimilarsBrexitCareersClinical trialsCompassionate useCompliance and inspectionsCorporateData on medicinesEarly accessFeesGeneric and hybrid medicinesGovernanceInnovationMaximum residue limitMedication errorMedicines for use outside the EUMedicine shortagesMpoxPaediatricsParallel distributionPharmacovigilanceProcurementProduct informationQuality of medicinesRare diseasesReferralsRegulatory and procedural guidanceResearch and developmentScientific adviceScientific guidelinesSMEVaccinesVeterinary limited marketsDiseases areaDiabetesViral diseasesCancerCardiovascular diseasesHIV and AIDSImmune-system diseasesNeurodegenerative diseasesTreatment of human immunodeficiency virus type 1 (HIV-1) infectionResponsible bodyCHMPPRACManagement BoardCATCMDhCOMPCVMPHMPCPDCOPatient safetyYesFiltersResults (7) PaxlovidSort byLast update date (new to old)Last update date (old to new)A-ZZ-AETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-29 December 2022NewsHumanCOVID-19MedicinesEMA Management Board: highlights of March 2022 meeting18 March 2022NewsCorporateCOVID-19: EMA recommends conditional marketing authorisation for Paxlovid28 January 2022NewsHumanCOVID-19MedicinesEMA receives application for conditional marketing authorisation for Paxlovid (PF-07321332 and ritonavir) for treating patients with COVID-1910 January 2022NewsHumanCOVID-19MedicinesMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 202117 December 2021NewsHumanCOVID-19MedicinesEMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19: rolling review starts in parallel16 December 2021NewsHumanCOVID-19MedicinesEMA starts review of Paxlovid for treating patients with COVID-1919 November 2021NewsHumanCOVID-19Medicines
ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-29 December 2022NewsHumanCOVID-19Medicines
COVID-19: EMA recommends conditional marketing authorisation for Paxlovid28 January 2022NewsHumanCOVID-19Medicines
EMA receives application for conditional marketing authorisation for Paxlovid (PF-07321332 and ritonavir) for treating patients with COVID-1910 January 2022NewsHumanCOVID-19Medicines
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 202117 December 2021NewsHumanCOVID-19Medicines
EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19: rolling review starts in parallel16 December 2021NewsHumanCOVID-19Medicines
EMA starts review of Paxlovid for treating patients with COVID-1919 November 2021NewsHumanCOVID-19Medicines